Please assess the completion status of the following clinical trial:

Trial Title: PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects, 18-75 years of age at time of Screening who provide written informed consent prior to initiation of any study procedure~2. Histologically confirmed metastatic adenocarcinoma originating from the colon or the rectum~3. Presence of at least 1 measurable reference lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria~4. Experienced PR or stable disease during first-line treatment with a systemic chemotherapy regimen and 1 biological therapy regimen~5. Maintenance therapy with a fluoropyrimidine (5-fluorouracil or capecitabine) plus the same biologic agent (bevacizumab, cetuximab or panitumumab) used during induction, scheduled to initiate prior to the first day of treatment with the study drug~6. No more than 1 line of chemotherapy regimen for mCRC (adjuvant therapy for non-metastasized disease is allowed if terminated more than 6 months before Screening and without recurrence within 6 months after the end of adjuvant treatment)~7. Last CT scan at 3 weeks or less before the first day of treatment~8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~9. Women of childbearing potential must agree to appropriately use an effective form of contraception (failure rate of \<1% per year) for 3 months from the day of the treatment. An effective form of contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, cervical cap or condom~10. Men must agree to use an effective form of contraception (as defined above), and not donate sperm for 3 months from the day of the treatment~11. White blood cell count ≥3.0 × 109/L with neutrophils ≥1.5 × 109/L~12. Platelets ≥100 × 109/L, hemoglobin ≥5.6 mmol/L (corresponding to 9 g/dL)~13. Serum bilirubin ≤1.5 × upper limit of normal (ULN) set by the site~14. Alanine amino transferase (ALAT) and aspartate amino transferase (ASAT) ≤2.5 × ULN in the absence of liver metastases. ALAT and ASAT ≤5 × ULN set by the site in the presence of liver metastases~15. Serum creatinine ≤1.5 × ULN set by the site and creatinine clearance \>30 mL/min using Cockroft formula~16. Relevant toxicities of prior therapies must have resolved, except for oxaliplatin-related neuropathy or alopecia~17. Anticipated life expectancy ≥6 months Subject is willing and able to comply with the requirements of the protocol~Exclusion Criteria:~1. Received chronic systemic immune therapy or immunosuppressant medication other than steroids within the last 6 weeks prior to start of study treatment~2. Received continuous systemic steroid treatment within the last 2 weeks prior to start of study treatment~3. Colorectal cancer with documented high microsatellite instability (MSI-H)~4. Colorectal cancer with documented BRAF mutations~5. Pre-existing systemic autoimmune or antibody-mediated diseases or immune deficiency diseases~6. Central nervous system (CNS) metastases~7. Active or uncontrolled severe infections or undiagnosed febrile condition \>38ºC~8. Acute or subacute intestinal obstruction or history of chronic intestinal inflammatory diseases~9. Symptomatic peritoneal carcinomatosis~10. Peritonitis~11. Serious, non-healing wounds, ulcers or bone fractures~12. Nephrotic syndrome~13. Arterial thromboembolisms or severe hemorrhages within 6 months before study enrolment (except bleeding tumor before tumor resection surgery)~14. Hemorrhagic diathesis or thrombotic tendency~15. Major surgery or radiotherapy within 12 weeks prior to the study treatment or anticipation of needing such procedure during the study period~16. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage more than once every 28 days~17. Participants with active malignancy (other than colorectal cancer) or a prior malignancy within the past 12 months~18. Participant with myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to the first dose of study treatment, any electrocardiogram (ECG) abnormality at Screening must be documented by the investigator as not medically relevant~19. Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation of a live attenuated vaccine will be required during the study~20. Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study~21. Known hypersensitivity to any component of the investigational drug~22. If female, participant is pregnant (exclusion confirmed with beta-human chorionic gonadotropin \[hCG\] test) or lactating at the time of enrollment, or has plans to become pregnant or start breastfeeding during the study~23. Pre-existing alcohol or drug abuse~24. Medical or mental impairments which make it impossible to obtain the patient's consent or to conduct the study~25. A significant concomitant medical condition which the clinical investigator believes precludes the patient from enrolling in the study Absent or limited legal competence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PolyPEPI1018 CRC Vaccine (Type: EXPERIMENTAL): The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses.

Based on this trial design, predict the completion outcome and termination type (if applicable).